隐瞒关键信息,诺和诺德索赔8.3亿美元

国际金融报
21 Feb

近日,丹麦制药企业诺和诺德的一则诉讼案引起业内广泛关注。诺和诺德拟向一家总部位于新加坡的Biotech企业KBP Biosciences(下称“KBP”)索赔8.3亿美元。隐瞒关键临床试验信息时间回到2023年,诺和诺德曾于当年10月以13亿美元的高价从KBP引进了一款用于治疗高血压和肾病药物Ocedurenone。彼时,诺和诺德全球总裁兼首席执行官周赋德曾表示,针对仍存在大量未被满足医疗需求的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10